A Phase II Study of Oxaliplatin Combined with Continuous Infusion Topotecan for Patients with Previously Treated Ovarian Cancer

BACKGROUND: Phase II trials suggest that prolonged intravenous (IV) infusion of the topoisomerase-1 inhibitor topotecan may be less toxic than when given by standard IV bolus 5-day administration. Oxaliplatin exhibits efficacy in platinum- pretreated disease and shows preclinical synergy with topois...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Stein, Stacey M., Tiersten, Amy, Hochster, Howard S., Blank, Stephanie V., Pothuri, Bhavana, Curtin, John, Shapira, Ilan, Levinson, Benjamin, Ivy, Percy, Joseph, Benson, Guddati, Achuta K., Muggia, Franco
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3869398/
https://ncbi.nlm.nih.gov/pubmed/24172094
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/IGC.0b013e3182a809e0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados